STAAR Surgical Files Proxy Materials

TL;DR

STAAR Surgical filed proxy docs on 12/17/25, no fee required.

AI Summary

STAAR Surgical Company filed a Definitive Additional Materials proxy statement on December 17, 2025. This filing indicates that no fee was required for this filing. The company, incorporated in Delaware, is a manufacturer of ophthalmic goods.

Why It Matters

This filing is a routine regulatory submission for STAAR Surgical Company, providing necessary documentation for shareholder communication and corporate governance processes.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement, indicating routine corporate activity rather than significant financial or operational changes.

Key Players & Entities

• STAAR Surgical Company (company) — Registrant
• 1911 Walker Ave (location) — Business and Mailing Address
• Monrovia, CA 91016 (location) — Business and Mailing Address
• DE (location) — State of Incorporation
• 1227 (date) — Fiscal Year End
• December 17, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $30.75 — oice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downsi

Filing Documents

• d42123ddefa14a.htm (DEFA14A) — 38KB
• g42123g1217093801317.jpg (GRAPHIC) — 3KB
• 0001193125-25-322104.txt ( ) — 43KB

Forward-Looking Statements

Forward-Looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR's stock pr

View Full Filing

View this DEFA14A filing on SEC EDGAR